Bilayer Tablet Formulation for Rosuvastatin and Ezetimibe Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating a solid dosage form of rosuvastatin and ezetimibe that is bioequivalent to individual consumption is challenging due to rosuvastatin's oxidative and moisture-mediated degradation, ezetimibe's insolubility, and interactions between microcrystalline cellulose and ezetimibe, which affect drug release and stability.
Innovation Solution
A bilayer tablet formulation with rosuvastatin formulated using microcrystalline cellulose and ezetimibe dissolved and mounted on lactose, separated from rosuvastatin to enhance solubility and stability, ensuring similar dissolution profiles and bioequivalence to individual tablets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If rosuvastatin and ezetimibe are combined in a single solid dosage form, then patient compliance and ease of administration are improved, but drug stability and solubility are compromised
Solution Approach 1:
The patent divides the single dosage form into two distinct layers: a rosuvastatin layer containing rosuvastatin calcium with microcrystalline cellulose, and an ezetimibe layer containing ezetimibe with lactose. This segmentation prevents direct interaction between the two drugs, maintaining their individual stability while delivering both medications in a single tablet.
Solution Approach 2:
The patent uses different excipients as intermediaries for each drug: microcrystalline cellulose for rosuvastatin and lactose for ezetimibe. These intermediaries are selected to be compatible with each specific drug, preventing degradation and maintaining solubility characteristics while allowing both drugs to coexist in the same tablet.
2Ease of manufacture
If microcrystalline cellulose is used as a filler for rosuvastatin, then tablet formulation is simplified, but ezetimibe solubility and drug release are retarded
Solution Approach 1:
The patent separates the formulation into two distinct layers, allowing microcrystalline cellulose to be used exclusively in the rosuvastatin layer where it provides excellent bulking and compression properties, while the ezetimibe layer uses lactose as the filler, ensuring optimal solubility and release characteristics for ezetimibe without interference from cellulose.
Solution Approach 2:
The patent applies different excipient qualities to different regions (layers) of the tablet: the rosuvastatin layer has the local quality of being formulated with microcrystalline cellulose for optimal rosuvastatin delivery, while the ezetimibe layer has the local quality of being formulated with lactose for optimal ezetimibe solubility and release. Each layer is optimized for its specific drug's requirements.
3Device complexity
If rosuvastatin and ezetimibe are formulated together in the same layer, then manufacturing process is simplified, but oxidative degradation and moisture-mediated degradation increase
Solution Approach 1:
The patent uses a bilayer tablet manufacturing process where two separate formulations are prepared in distinct layers. The rosuvastatin layer and ezetimibe layer are manufactured separately with their respective excipients and stability profiles, then compressed together in a single tablet. This segmentation protects rosuvastatin from oxidative degradation and both drugs from moisture-mediated degradation by preventing direct interaction.
Solution Approach 2:
The patent introduces physical separation as an intermediary mechanism between rosuvastatin and ezetimibe. The bilayer structure acts as a physical barrier that prevents harmful oxidative and moisture-mediated interactions while still allowing both drugs to be delivered in a single dosage form. Each layer maintains its own chemical environment optimized for drug stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bilayer tablet formulation achieves bioequivalence and stability, reducing cholesterol levels and cardiovascular risk by maintaining the same Area Under Curve (AUC) as individual tablets, overcoming solubility and stability issues of the combined form.
Implementation Method 1
ezetimibe dissolved and mounted on lactose
Data Source
Figure 1
AI summary
The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active ingredients taken together individually orally, and pharmaceutically acceptable additives suitable for the preparation. In preferred embodiments of this invention, the rosuvastatin is in the form of rosuvastatin calcium and the pharmaceutically acceptable additives are selected from diluents, disintegrants, glidants, lubricants, colorants and combinations thereof.